Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.72 USD
-0.03 (-1.43%)
Updated May 21, 2024 04:00 PM ET
After-Market: $1.71 -0.01 (-0.58%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MIST 1.72 -0.03(-1.43%)
Will MIST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
Other News for MIST
Milestone Pharmaceuticals’ Strong Buy Rating: CARDAMYST’s FDA Resubmission and Bright Revenue Prospects
MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q1 2024
Milestone Pharmaceuticals Excels with New Drug Update
Milestone Pharmaceuticals GAAP EPS of -$0.21 beats by $0.05
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update